Skip to main content
GWGovwatch
CongressBillsCommitteesPresidentMoneyPulseMisconductElectionsMap
Donate

Weekly accountability digest

One email a week with new votes, moving bills, and misconduct updates. No spam.

GW

Govwatch. Public data about Congress, in one place, in plain English.

Built with public data. Not affiliated with the U.S. government.

Explore

  • Officials
  • Legislation
  • Committees
  • Congress Pulse
  • Trending Topics
  • Bipartisan Leaderboard
  • Weekly Digest
  • Misconduct
  • Predictions

Learn

  • How Congress Works
  • How a Bill Becomes Law
  • Campaign Finance 101
  • Glossary

Tools

  • My Representatives
  • Compare Members
  • Bill Watchlist
  • Search
  • District Map
  • Follow the Money
  • Watch Live

Site

  • About
  • Contact
  • Corrections
  • Privacy Policy
  • Terms of Service

Data Sources

Congress.gov API v3
Bills, members, votesGovInfo API
Floor speeches, reports, bill textFederal Election Commission (FEC)
Campaign financeVoteView (UCLA)
Ideology scores (DW-NOMINATE)GovTrack.us
Misconduct data (CC0)U.S. Census Bureau
District demographics

Data Last Updated

Bills & Votes: Less than 1 hour ago
Support This Project

This site is free. Donations help cover hosting, API fees, and keeping the data fresh.

All data is sourced from official government APIs and public records. This site is for informational purposes only.

© 2026 Govwatch

S5059Referred to Committee

A bill to amend the Public Health Service Act to streamline the review of biosimilar biological products.

Share:
Introduced
In Committee
3
Passed One Chamber
4
Passed Both
5
Signed into Law
119th
Congress
2026-07-21
Introduced
3
Cosponsors
S
ⓘ
Type

Sponsor

Ashley Moody
Ashley Moody
Republican · FL · Senator
Votes with party: 75.1% (843 recorded votes)
Top industries funding sponsor:
  • Conservative Groups$11,211k
  • Progressive Groups$1,500k

Full profile: /officials/M001244

Source: Congress.gov · FEC

Cosponsors (3)

Members who have signed on to support this bill since introduction. Source: Congress.gov.

  • Angela D. Alsobrooks (D-MD)Original· 2026-07-21
  • Lisa Blunt Rochester (D-DE)Original· 2026-07-21
  • Rick Scott (R-FL)Original· 2026-07-21

Latest Action

The most recent step in the bill's legislative path. Committee Activity below shows referrals and reports; the full action-by-action history including floor proceedings lives at Congress.gov →

Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

2026-07-21

Source: Congress.gov

Committee Activity

Currently in

  • Senate Committee on Health, Education, Labor, and PensionsReferred To · 2026-07-21

Plain-English Summary

The bill would speed up the government's approval process for biosimilar drugs, which are lower-cost versions of expensive biologic medications that work similarly to the originals. This change would help patients and insurance companies access more affordable treatment options more quickly, while giving pharmaceutical companies a clearer pathway to bring these alternative drugs to market.

AI-assisted summary generated from the official bill metadata (title, subjects, actions) sourced from Congress.gov. Cached and reviewed. Always verify against the official text linked below.

Full bill text is not yet cached locally.
Open text viewRead on Congress.gov

Related legislation

Bills by the same sponsor or covering overlapping subjects.

  • S5058A bill to amend title 49, United States Code, to prohibit staged collisions with commercial motor vehicles, and for other purposes.
    Referred to Committee · 2026-07-21
  • S5001A bill to amend the Help America Vote Act of 2002 to require ballots in elections for Federal office to be received by the close of the polls on the date of election.
    Referred to Committee · 2026-07-15
  • S4905Space Ready 2.0 Act
    Referred to Committee · 2026-06-24
  • S4907TRADES Act
    Referred to Committee · 2026-06-24